Navigation Links
Dacogen(R) (decitabine for injection) Data Presented on a Phase II Clinical Trial in Elderly Patients with Acute Myeloid Leukemia (AML)
Date:12/8/2008

Response Observed Across All Subtypes of AML, Including Those with Poorest Prognoses

SAN FRANCISCO, Dec. 8 /PRNewswire/ -- Eisai Corporation of North America today announced data from a Phase II trial evaluating a five-day dosing regimen of Dacogen(R) (decitabine for injection) in acute myeloid leukemia (AML), the most common form of leukemia. The study involved elderly patients with AML, who often have limited options due to comorbidities and are typically considered ineligible for standard induction chemotherapy. These data were presented today at the American Society of Hematology (ASH) 50th Annual Meeting.

Dacogen(R) is indicated for treatment of patients with myelodysplastic syndromes (MDS), including those with refractory anemia with excess blasts (immature or unformed blood cells) in transformation (RAEB-T - now re-classified by World Health Organization [WHO] as AML). Phase II and III clinical trials evaluating Dacogen(R) in patients with AML are currently underway.

Data from the Phase II study reported a complete response rate of 24 percent. A complete response designation requires that the patient have less than 5 percent blasts in the marrow, no evidence of disease outside of the bone marrow and absolute neutrophil and platelet counts of more than 1,000/uL and 100,000/uL, respectively. The majority of patients in the trial had intermediate or poor risk cytogenetics (bone marrow tests to identify abnormal chromosomes), which are associated with poor prognoses. Responses were observed across all patients including those with poor risk cytogenetics, those whose AML transformed from MDS, or those who developed AML after previous treatment for cancer. The results presented at ASH provide additional support for the ongoing investigation of Dacogen(R) in a Phase III trial currently underway in elderly patients with AML.

"We are enthusiastic about these new data prese
'/>"/>

SOURCE Eisai Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
2. Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
3. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
4. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
5. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
6. New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Data
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
9. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
10. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
11. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)...  iMD Companies, Inc. (ICBU) has repositioned itself as a holding ... a foothold in the hydroponic, hemp and medical marijuana sectors. ... in the sector, and recently partnering with the Chippewa Tribe ... medical marijuana, iMD is committing to bring its vision to ...
(Date:1/23/2015)... Africa , Jan. 23, 2015   Leatt Corporation ... personal protective equipment for all forms of sports, including ... Leatt-Brace® neck brace, announced today that the UISP Lega ... now requires all riders to wear a neck brace ...
(Date:1/23/2015)... 23, 2015 Gem Pharmaceuticals announced today that the ... into the Company,s Phase 2 clinical trial.  This open-label ... lead compound, GPX-150 (an investigational medication), in approximately 30 ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... , , , ... ) today announced that in a large, randomized, double-blind, placebo-controlled, Phase ... dialysis), anemia and type-2 diabetes (the T rial to ... T herapy, or TREAT), treatment of anemia with Aranesp((R) )(darbepoetin alfa) ...
... , , RIDGEFIELD, Conn., Aug. ... of Long-Term Anticoagulant Therapy, Warfarin, Compared to Dabigatran)(1) study will ... in Barcelona on Sunday, Aug. 30. The primary objective ... the investigational oral direct thrombin inhibitor, dabigatran etexilate, against the ...
Cached Medicine Technology:Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 2Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 3Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 4Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 5Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 6Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 7Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 8Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 2Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 3Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 4Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 5Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 6Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 7
(Date:1/22/2015)... 22, 2015 For over 20 years, Dr. David ... and Vista area has treated just about every type of ... circumstances. And for those same twenty-plus years, the team at ... those injuries with the best possible doctor. With the ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Joan Lunden, ... keynote speaker at the upcoming 32nd Annual Miami ... Physicians’ Education Resource®, LLC (PER®) , shares that ... have gone undetected if she had not followed up ...
(Date:1/22/2015)... La Jolla, Calif. (PRWEB) January 22, 2015 ... and Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen ... (CHI) for their leadership in advancing biotechnology, biomedical ... Mitchell, Bonilla and Olsen each received the “2014 ...
(Date:1/22/2015)... Florida (PRWEB) January 22, 2015 IsoComforter, Inc. ... therapy machine with patented IsoTube design to treat specific body ... introduced the most progressive and easy to use patented cold ... post-operative and sports related orthopedic and muscle injuries. IsoComforter ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Payday lending ... vulnerable communities and cause financial distress to the states ... analysts at Howard University’s Center on Race and Wealth. ... in economic activity, payday loans at the same time ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
... ... ... ... ...
... Research (AADR) has announced David C. Johnsen, dean of the ... the 2010 AADR Jack Hein Public Service Award. This award ... Meeting & Exhibition in Washington, DC, March 3, 2010. ... Institutes of Health and the National Institute of Dental and ...
... Research (AADR) has announced Irwin D. Mandel, AADR past president ... of the inaugural 2010 AADR Distinguished Mentoring Award. This award ... in Washington, DC, March 3, 2010. Mandel began ... up his part-time private practice in 1968 to devote himself ...
... pathway discovery could lead to new treatments, study suggests , ... new treatments for cystic fibrosis, U.S. researchers have identified a ... inherited lung disease. , Cystic fibrosis causes thick, sticky mucus ... is one of the most common potentially lethal genetic diseases ...
... ... ... ... ...
... $2 ... ... of the 2010 U.S. Ambulatory EHR Study, a strategic analysis of the U.S. Ambulatory EHR ... of the American Recovery and Reinvestment (ARRA) Act. ,As recently presented at the Piper Jaffray ...
Cached Medicine News:Health News:Figure Skating Standards Foster Eating Disorders, Says Kimberly Dennis, M.D. 2Health News:Figure Skating Standards Foster Eating Disorders, Says Kimberly Dennis, M.D. 3Health News:Figure Skating Standards Foster Eating Disorders, Says Kimberly Dennis, M.D. 4Health News:Figure Skating Standards Foster Eating Disorders, Says Kimberly Dennis, M.D. 5Health News:Figure Skating Standards Foster Eating Disorders, Says Kimberly Dennis, M.D. 6Health News:Figure Skating Standards Foster Eating Disorders, Says Kimberly Dennis, M.D. 7Health News:Figure Skating Standards Foster Eating Disorders, Says Kimberly Dennis, M.D. 8Health News:Drug Improved Survival in Mice With Cystic Fibrosis 2Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 2Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 3Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 4Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 5Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 6Health News:CapSite Announces Release of the 2010 U.S. Ambulatory EHR Study 2
Reciprocating shaker specifically for platelet bags....
EIA Kit for the detection of progesterone....
... Progesterone is a steroid produced by ... testes and the placenta. As with other ... a series of enzyme-mediated steps [1,2]. Progesterone ... is almost immediately shunted into other steroidogenic ...
No cross-reaction with human pro-insulin and C-peptide....
Medicine Products: